A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 453 participants.

Also called NCT03175120

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 453 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03175120
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
China, Hong Kong SAR China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03175120. Randomized; double masking; primary purpose treatment. Start 2017-05-26 (actual); primary completion 2019-03-05 (actual). Results posted on 2020-03-19.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD)
Acronym
DUAL™ II China
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Insulin degludec/liraglutide
Intervention (Drug)
Insulin degludec
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct03175120
Content hash
4b87940a4791f5b7d094c728c87245a6d3689951d69a084ab4fc73f8285e5300